AP PHOTOS: The Black hair industry imports products from China. Here's what tariffs mean
Many Black women have hair types and workplace-favored styles that require careful attention. They can spend hundreds of dollars at salons each month on extensions, weaves, wigs and braids.
Most hair salon tools and packaging is imported from China.
Stylists are considering raising their prices while the the U.S. and China negotiate new trade agreements. But many dread what price increases will do for clients who are lower income and already strained by months of inflation on virtually everything else.
This is a photo gallery curated by AP photo editors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
McDonald's is adding a Spicy McMuffin to its breakfast lineup
You can find original article here Nrn. Subscribe to our free daily Nrn newsletter. McDonald's 50th anniversary celebration of its signature Egg McMuffin continues with the introduction of a Spicy McMuffin, available starting July 8 at participating restaurants for a limited time. The offering includes melted cheese, an egg, Canadian bacon, and Spicy Pepper Sauce served on a toasted and buttered English Muffin. The summer lineup also includes the Spicy Sausage McMuffin and the Spicy Sausage McMuffin with Egg. According to the company, the popular Egg McMuffin was created by Herb Peterson, a franchisee in Santa Barbara, Calif., who presented the concept to founder Ray Croc in 1971. The idea was to create a portable Eggs Benedict. Breakfast is a priority for McDonald's value platform, as its McValue menu, introduced in January, includes items like the Sausage McMuffin, Sausage Biscuit, Sausage Burrito, and Hash Browns, available for a "Buy One, Add One for $1" deal. During the company's fourth quarter earnings call earlier this year, chief financial officer Ian Borden said breakfast has been a strong daypart for the domestic business. 'It's an area where we're taking share,' he said. During the first quarter earnings call in late April, however, chief executive officer Chris Kempczinski said there has been a decline in frequency during the 'bellwether' breakfast daypart. 'Morning now is a place that you're seeing people are choosing either to skip breakfast or they're choosing to eat at home for breakfast. And I think that's more to explain what's going on in the U.S. versus any kind of segment shift,' he said. The Spicy McMuffin comes on the heels of two other menu launches for McDonald's, a new Blueberry & Crème Pie and a new premium burger called the Daily Double. These launches come as the chain has experienced two rare and consecutive quarters of same-store sales declines and traffic softness. Contact Alicia Kelso at Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy
Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In the last twelve months, the biggest single sale by an insider was when the Executive VP & President of Commercial Health Benefits, Charles Kendrick, sold US$3.2m worth of shares at a price of US$432 per share. That means that an insider was selling shares at around the current price of US$396. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Elevance Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar). Over the last three months, we've seen significant insider selling at Elevance Health. Specifically, Executive VP & CFO Mark Kaye ditched US$1.9m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$103m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. An insider hasn't bought Elevance Health stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Elevance Health. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
14 minutes ago
- Yahoo
US open to 'creative solutions' on pharma trade with EU, Irish minister says
By Conor Humphries DUBLIN (Reuters) -U.S. Trade Representative Jamieson Greer made clear in a meeting with Irish Trade Minster Simon Harris last month that Washington was open to "creative solutions" on pharmaceutical trade between the U.S. and European Union, Harris said on Wednesday. "He made it clear that he was open to creative solutions when it comes to pharma and I think that's an important recognition that actually pharma between the U.S. and the EU, the U.S. and Ireland, is much more interdependent than perhaps people were led to believe in certain quarters at the start of this process," Harris told reporters. The European Union wants immediate relief from tariffs in key sectors as part of any trade deal with the U.S. due by a July 9 deadline, EU diplomats have told Reuters, even as they accept the U.S. baseline tariff of 10% as unavoidable. The EU also wants a deal to cover commercial aircraft and parts, pharmaceuticals and semiconductors, sectors the U.S. is investigating, but has not yet imposed extra duties on. Trump said in June the pharma duties would be announced "very soon". "I think it's important to be truthful with people, the EU is negotiating with an administration that believes in tariffs and clearly I think 10% seems to be the baseline in any agreement they (the U.S.) have reached so far," Harris said. "But we will be seeking at an EU level to maximise the number of sectors where there is zero-for-zero (tariffs)." Harris highlighted pharma, aviation and agriculture as areas Dublin would like trade between the EU and U.S. to flow freely. He added that there was a welcome intensity to the talks between the EU and U.S. and that while a brief extension to the July 9 deadline is something that can considered, it would be preferable to at the very least deliver a framework agreement and set forward a roadmap for further engagement on key sectors.
